Posts

Mount Sinai researchers find more than 4,700 gene clust...

New York, NY (November 13, 2023)—Researchers at the Mount Sinai Center for Trans...

Refreshing a computer chip to a “chiplet”

For the average consumer, the life cycle of a computer starts when the system is...

Is there a physiological explanation behind experiencin...

What is glare? Simply put, glare is visual discomfort often leading to annoyance...

University of Oklahoma engineer elected as fellow membe...

Optica, an international association in optics and photonics, recently announced...

NJIT scientists uncover aurora-like radio emission abov...

In a study published in Nature Astronomy, astronomers from New Jersey Institute ...

Capturing wellhead gases for profit and a cleaner envir...

Burning of natural gas at oil and gas wells, called flaring, is a major waste of...

The Long Jump: Athletic, insect-scale long jumping robo...

A team of engineers from the University of Illinois has published the first know...

A how-to for reducing flooding impacts in coastal towns

A University of Texas at Arlington civil engineering researcher is determining w...

Using deep learning to process raw photoacoustic channe...

Cardiovascular diseases rank among the top causes of death across the world, and...

UTA developing more powerful rocket engines for space t...

A University of Texas at Arlington engineering researcher has received a NASA gr...

Researchers propose MOF modular customization strategy ...

Membrane separation technology offers great potential due to its low energy cons...

Tandem single atom electrocatalyst realizes reduction o...

The electrochemical CO2 reduction reaction (CO2RR) into carbon-based fuels provi...

Bristol Myers Squibb’s CAR-T Breyanzi wins FDA priority...

The US Food and Drug Administration (FDA) has granted priority review for B...

BIO-Europe 2023: Barriers remain in the AI pharma revol...

Despite the shift towards artificial intelligence (AI) in drug discovery and de...

Novartis’ urticaria drug meets all endpoints in Phase I...

Novartis’ remibrutinib met all the primary and secondary endpoints at 12 weeks ...

AstraZeneca posts 16% drop in Q3 2023 profit after tax

AstraZeneca has posted a profit after tax of $1.37bn for the third quarter (Q3)...